A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects with Refractory Non-Hodgkin Lymphoma

被引：0
|
作者：
Young, Patricia A.
Mataveli, Fabio D.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-137784
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] A phase 1, open-label, dose-escalation study of pralatrexate incombination with bortezomib in patients with relapsed/refractory multiple myeloma
    Dunn, Tamara J.
    Dinner, Shira
    Price, Elizabeth
    Coutre, Steven E.
    Gotlib, Jason
    Hao, Ying
    Berube, Caroline
    Medeiros, Bruno C.
    Liedtke, Michaela
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (02) : 253 - 259
  • [32] A phase 1/2, open-label, dose-escalation, safety and tolerability study of NC410 in subjects with advanced or metastatic solid tumors.
    Gutierrez, Martin
    Janku, Filip
    Tian, Linjie
    Luke, Jason J.
    Shum, Elaine
    Shin, John
    Weiss, Ido
    Liu, Linda N.
    Files, Dallas
    Langermann, Solomon
    Myint, Han
    Bilusic, Marijo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [33] A phase I, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, and pharmacodynamics of oral azacitidine in subjects with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML)
    Skikne, B. S.
    Ward, M. R.
    Nasser, A.
    Aukerman, L.
    Garcia-Manero, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [34] A Phase I, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AMG 986 in Healthy Japanese Subjects
    Trivedi, Ashit
    Mather, Omar
    Vega, Silvia
    Hutton, Shauna
    Hellawell, Jennifer
    Lee, Edward
    DRUGS IN R&D, 2022, 22 (02) : 141 - 146
  • [35] A Phase I, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AMG 986 in Healthy Japanese Subjects
    Ashit Trivedi
    Omar Mather
    Silvia Vega
    Shauna Hutton
    Jennifer Hellawell
    Edward Lee
    Drugs in R&D, 2022, 22 : 141 - 146
  • [36] A phase 1, open-label, dose-escalation, multicenter study to evaluate the tolerability, safety, pharmacokinetics, and activity of ADCT-301 in patients with relapsed or refractory CD25-positive acute myeloid leukemia.
    Tallman, Martin S.
    Feingold, Jay Marshall
    Spira, Alexander I.
    Rizzieri, David
    Atallah, Ehab L.
    Stock, Wendy
    Jain, Nitin
    Walter, Roland B.
    Chung, Ki Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [37] A phase 1 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of MEDI7247 in patients with select relapsed/refractory hematologic malignancies.
    Fathi, Amir Tahmasb
    Donnellan, William Bruce
    Lyons, Roger M.
    Maris, Michael B.
    Kim, Tae Min
    Kim, Won Seog
    Schiller, Gary J.
    Abboud, Camille N.
    Arellano, Martha Lucia
    Cull, Elizabeth H.
    Yee, Karen W. L.
    Townsley, Danielle Michelle
    Wang, Fujun
    Bothos, John G.
    Yao, Nai-Shun
    Salles, Gilles A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial
    Imamura, Keiko
    Izumi, Yuishin
    Nagai, Makiko
    Nishiyama, Kazutoshi
    Watanabe, Yasuhiro
    Hanajima, Ritsuko
    Egawa, Naohiro
    Ayaki, Takashi
    Oki, Ryosuke
    Fujita, Koji
    Uozumi, Ryuji
    Morinaga, Akiko
    Hirohashi, Tomoko
    Fujii, Yosuke
    Yamamoto, Takuya
    Tatebe, Harutsugu
    Tokuda, Takahiko
    Takahashi, Naoto
    Morita, Satoshi
    Takahashi, Ryosuke
    Inoue, Haruhisa
    ECLINICALMEDICINE, 2022, 53
  • [39] A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma
    Shira Dinner
    Tamara J. Dunn
    Elizabeth Price
    Steven E. Coutré
    Jason Gotlib
    Caroline Berube
    Gregory P. Kaufman
    Bruno C. Medeiros
    Michaela Liedtke
    International Journal of Hematology, 2018, 108 : 267 - 273
  • [40] A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma
    Dinner, Shira
    Dunn, Tamara J.
    Price, Elizabeth
    Coutre, Steven E.
    Gotlib, Jason
    Berube, Caroline
    Kaufman, Gregory P.
    Medeiros, Bruno C.
    Liedtke, Michaela
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2018, 108 (03) : 267 - 273
12345